Results 21 to 30 of about 6,463,095 (311)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]
JNCI: Journal of the National Cancer Institute, 2009 Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire +2 more sources
Bias in progression‐free survival analysis due to intermittent assessment of progression [PDF]
Statistics in Medicine, 2015 Cancer clinical trials are routinely designed to assess the effect of treatment on disease progression and death, often in terms of a composite endpoint called progression‐free survival. When progression status is known only at periodic assessment times, the progression time is interval censored, and complications arise in the analysis of progression ...
Zeng, Leilei +3 more
openaire +2 more sources
Cancer Treatment and Research Communications, 2021 Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj +1 more source
, 2022 Progression-free survival and overall survival of adult and pediatric patients with intracranial germinoma.
Chun-Fu Lin (12174572) +11 more
core +1 more source
Cancer Cell International, 2021 Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini +6 more
doaj +1 more source
Progression‐free survival as a surrogate marker of overall survival [PDF]
Cancer, 2011 The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire +2 more sources
Overall survival and progression-free survival.
, 2022 Overall survival and progression-free survival.
Leana Terblanche (13132388) +1 more
core +1 more source
Frontiers in Nutrition, 2023 BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie +16 more
doaj +1 more source
The Application of Clinical Genetics, 2022 Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS +10 more
doaj
Progression-free survival analysis.
, 2019 Progression-free survival analysis.
Donglin Zhu (231422) +5 more
core +1 more source